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Background. The purpose of this study was to prove the feasibility of a longmer oligonucleotide microarray platform to profile
gene copy number alterations in prostate cancer cell lines and to quickly indicate novel candidate genes, which may play a role
in carcinogenesis. Methods/Results and Findings. Genome-wide screening for regions of genetic gains and losses on nine
prostate cancer cell lines (PC3, DU145, LNCaP, CWR22, and derived sublines) was carried out using comparative genomic
hybridization on a 35,000 feature oligonucleotide microarray (arrayCGH). Compared to conventional chromosomal CGH, more
deletions and small regions of gains, particularly in pericentromeric regions and regions next to the telomeres, were detected.
As validation of the high-resolution of arrayCGH we further analyzed a small amplicon of 1.7 MB at 9p13.3, which was found in
CWR22 and CWR22-Rv1. Increased copy number was confirmed by fluorescence in situ hybridization using the BAC clone RP11-
165H19 from the amplified region comprising the two genes interleukin 11 receptor alpha (IL11-RA) and dynactin 3 (DCTN3).
Using quantitative real time PCR (qPCR) we could demonstrate that IL11-RA is the gene with the highest copy number gain in
the cell lines compared to DCTN3 suggesting IL11-RA to be the amplification target. Screening of 20 primary prostate
carcinomas by qPCR revealed an IL11-RA copy number gain in 75% of the tumors analyzed. Gain of DCTN3 was only found in
two cases together with a gain of IL11-RA. Conclusions/Significance. ArrayCGH using longmer oligonucleotide microarrays is
feasible for high-resolution analysis of chomosomal imbalances. Characterization of a small gained region at 9p13.3 in prostate
cancer cell lines and primary prostate cancer samples by fluorescence in situ hybridization and quantitative PCR has revealed
interleukin 11 receptor alpha gene as a candidate target of amplification with an amplification frequency of 75% in prostate
carcinomas. Frequent amplification of IL11-RA in prostate cancer is a potential mechanism of IL11-RA overexpression in this
tumor type.
Citation: Kamradt J, Jung V, Wahrheit K, Tolosi L, Rahnenfuehrer J, et al (2007) Detection of Novel Amplicons in Prostate Cancer by Comprehensive
Genomic Profiling of Prostate Cancer Cell Lines Using Oligonucleotide-Based ArrayCGH. PLoS ONE 2(8): e769. doi:10.1371/journal.pone.0000769
INTRODUCTION
Genetic alterations are believed to be key events in the develop-
ment of most tumors, including prostate cancer [1]. Tumor
progression seems to depend on the successive acquisition of
chromosomal aberrations leading to gains or losses of part of the
tumor cell genome. Characterization of these genomic abnormal-
ities in prostate cancer may therefore help to understand the
molecular pathogenesis and may unveil genetic markers of
progression.
Since its first description by Kallioniemi et al. (1992) [2]
chromosomal comparative genomic hybridization (cCGH) has
become the most frequently used technique to detect DNA copy
number changes in tumor genomes. We and others have analyzed
the genome of prostate cancer cell lines and primary prostate
cancer samples with this technique [3–5]. Fluorescence in situ
DNA hybridization (FISH) and quantitative real time PCR have
been demonstrated to be valuable tools for target gene discovery
within identified chromosomal regions of gain, e.g. the TLOC1/
SEC62 gene at 3q26.2 in prostate cancer [6]. Applying advanced
bioinformatic models on cCGH data demonstrated that the
patterns of chromosomal aberrations contain valuable prognostic
information of a tumor [7].
Because of the relative low spatial resolution (,20MB) of cCGH
and its inaccuracy in centromeric as well as telomeric regions this
technique is neither able to adequately detect small regions of
gains or loses nor genomic alterations next to the centromere or
telomere. Also, for target gene identification in gained regions as
found by cCGH, fine-mapping with techniques like FISH is
laborious and time-consuming.
Compared to cCGH, microarray-based CGH, referred to as
array CGH (aCGH) or matrix CGH [8–9], has a roughly 1.000-
fold higher resolution (or even higher) and allows analysis of
chromosomal regions close to the centromere and telomere.
Different approaches of aCGH have been followed over the years.
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have chosen cDNA or oligonucleotide arrays that were originally
designed for expression analysis [9,11]. Arrays designed for gene
expression are advantageous for direct comparison of genomic
alterations and gene expression on the same platform. Several
studies have demonstrated that this approach shows a significant
association between gene copy number and expression level
[12,13]. Lately, use of oligonucleotide arrays specifically for aCGH
designed longer was reported [14] and is now commercially
available as an aCGH platform. For the aCGH analyses of
prostate cancer cell lines as well as clinical specimens either BAC
or cDNA arrays have been utilized [12,13,15–20].
Here we present the first study utilizing a 35,000 feature 70-mer
oligonucleotide array, originally designed for expression analysis,
for detailed genomic characterization of nine prostate cancer cell
lines. Resulting aCGH profiles are compared to cCGH results.
The occurrence of a newly detected small amplicon in the
pericentromeric 9p13.3 subband in various cell lines is validated
by FISH and quantitative real time PCR and is also confirmed in
primary prostate cancer samples.
MATERIAL AND METHODS
Tumor cell lines and DNA isolation
The human prostate cancer cell lines DU145, PC3, LNCaP,
CWR22 and CWR22-Rv1 were obtained from American Type
Cell Culture Collection (ATCC, Rockville, MD, USA) and
cultured according to the protocols recommended by the ATCC.
From PC3 and DU145, two different branches were available, one
held in the laboratory of the Cancer Genetic Branch, NHGRI,
NIH (PC3NIH, DU145NIH), the other in the urological laboratory
in Homburg (PC3HOM, DU145HOM). PC3-N, PC-125-1L, and
DU145-MN1 were established as previously described [21,22].
LNCaP-CN4-2 was kindly provided by Z. Culig, Department of
Urology, Medical University, Innsbruck, Austria.
Primary prostate cancer samples
Quantitative gene copy number measurements were done on 20
primary prostate adenocarcinoma samples, which were obtained
after radical prostatectomy from previously untreated prostate
cancer patients. Following prostatectomy, the specimens were
dissected by a pathologist, snap frozen, and stored at 280uC. Only
samples containing .50% tumor cells were included in the study.
DNA isolation and quantification
DNA was isolated using the QiAmp DNA isolation kit (Qiagen,
Hilden, Germany) and subsequently quantified by a fluorometric
assay (Quant-iT Pico Green dsDNA Kit, Invitrogen, Karlsruhe,
Germany). Fluorescence was measured using a TECAN (Salzburg,
Austria) SpectrafluorPLUS microplate fluorescence reader with an
excitation wavelength of 485 nm and an emission wavelength of
535 nm. DNA concentrations were calculated from a standard
curve of double-stranded control DNA provided with the kit that
was measured in triplicate at the concentrations 30, 3, 0.3, and
0.03 ng/ml (measured by fluorometry).
Whole genome amplification and purification
A volume of 2.5 ml out of 4 ng/ml dilutions from cell lines and
control DNA was used as starting material for the amplification.
The phi29-amplification was carried out according to the Repli-G
kit manufacturer’s instructions (Qiagen) using an incubation time
of 16 h. Repli-G reactions were checked by a real time based intra
Alu-PCR assay. Additionally DNA concentration was fluorime-
trically quantified with Quant-iT Pico Green dsDNA Kit
(Invitrogen) and ranged between 10–30 mg.
Alu-PCR assay
Due to a frequently observed background synthesis in the Repli-G
amplified no-template control, we performed an extra quality
control on 1 ml (1:50 dilution) of unpurified phi29-amplified DNA.
An Alu specific band should be present in all Repli-G amplified
samples and absent in the Repli-G amplified no-template control.
Each 2 ml of sample was compared to 1 ml serial dilutions of male
control DNA (Promega, WI, USA) (10, 5, 2, 1, 0.5, 0.1, 0.01,
0.001 ng/ml). The 25 ml reactions contained 16Hot start SYBR
green master mix (Qiagen), 1.5 mM MgCl2, 0.2 mM dNTPs Mix,
400 nM primers each (Alu-forw: 59-GTGGGCTGAAAAGCTCC-
CGATTAT-39 and Alu-rev: 59-ATTCAAAGGGTATCTGGGC
TCTGG-39). The cycling conditions were as follows: 1 min at 94uC;
35 cycles of 20 s at 94uC, 20 s at 55uC and 20 s at 72uC; 10 min at
72uC. The amplification products were checked by melting curve
analysis using the LightCycler
TM quantification software 3.5 (Roche
Diagnostics, Mannheim, Germany) and gel electrophoresis. Ampli-
fication was considered successful when the amount of human Alu
sequences in phi29 generated DNA fragments ranged from 10–30%
and when a smear of DNA fragments, ranging from 1 to 20 kb, was
visible by gel electrophoresis.
ArrayCGH
10 mg of amplified and purified DNA were labeled using the
BioPrime Array CGH Genomic Labeling kit (Invitrogen) accord-
ing to the manufacturer’s instructions in a volume of 50 ml with
a modified dNTP mix containing 120 mM each of dATP, dGTP,
and dCTP; 60 mM dTTP; and 60 mM Cy5-dUTP or Cy3-dUTP.
Labeled DNA was purified using QIAquick PCR purification
columns (Qiagen). Tumor and reference DNA were pooled, mixed
with 50 mg Cot-1 DNA (Invitrogen) and concentrated to a volume
of 20 ml in a vacuum centrifuge. DNA was then mixed with an
equal amount of 26 formamide buffer, denaturated at 95uC for
5 min and preincubated at 37uC for 30 min in a waterbath.
Hybridizations were carried out on custom (printed at the
NHGRI/NIH Microarray Core Facility) glass slides containing
the Operon 70mer oligonucleotide set version 3 with 34.580
oligonucleotides. The oligonucleotides were originally designed for
expression analysis. For arrayCGH all oligonucleotides were
sequence aligned against the human genome (build 34), En-
sEMBL, RefSeq, dbEST and UCSC known genes resulting in
29.383 oligonucleotides with a specific chromosomal mapping.
DNA samples were hybridized onto the array for 16–18 hours
at 42uC utilizing the MAUI 4-bay hybridization system and
MAUI Mixer A0 (BioMicro System, Salt Lake City, UT, USA).
After hybridization arrays and MAUI Mixer were disassembled in
42uC1 6SSC and 0.05% SDS (wash solution 1) and subsequently
washed two times in wash solution 1 for 5 minutes followed by two
washes in 0.16SSC (wash solution 2) for 5 minutes. Dried array
slides were scanned using a ScanLite Express microarray scanner
(Perkin Elmer, Wellesley, MA, USA). Raw image files of the arrays
were processed using DeArray software [23] and resulting image
data were imported into R environment using bioconductor
packages [24] for further analysis.
Data processing and statistical analysis of
microarray data
The statistical analysis for identifying chromosomal regions with
altered copy numbers in single arrays consisted of two steps. First,
after mapping the measured gene copy number log-ratios to their
ArrayCGH of Prostate Cancer
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adaptive weights smoothing-based algorithm GLAD [25] for
identifying regions of constant copy number was used. This
algorithm fits a piecewise constant function along the chromosome
to the log-ratios. Then, for every sample regions that are amplified
or deleted were identified. Here, normal distributions were fitted
in a robust way to the smoothed log-ratios of each array. In
particular, the median and the interquartile range were calculated,
and a normal distribution was fitted to these parameters. Finally,
constant regions with values above or below specified cutoffs were
detected as gained or lost regions, respectively. In order to
discriminate between weak and strong signals, the median plus or
minus one or two standard deviations were selected as cutoffs for
weak and strong aberrations, respectively. The algorithms were
implemented in the R programming language (www.r-project.org).
The results were obtained using R version 2.3 and the GLAD
library provided by the Bioconductor project (www.bioconductor.
org), version 1.7.
Chromosomal CGH
Hybridization was done as described previously with minor
modifications [26]. 500 ng biotin labeled probe DNA, 500 ng
digoxigenin labeled reference DNA (human male reference DNA,
Promega, WI, USA) and 50 mg human unlabeled cot-DNA
(Invitrogen, Karlsruhe, Germany) were precipitated with 0.3 M
sodium acetate in the 2.5 fold volume of ethanol and dissolved in
2.5 ml deionized formamide. After 30 minutes, the 2.5 ml of the
double hybridization mix (100 mM sodium phosphate buffer,
46SSC and 20% dextrane sulfate, pH 7.0) were added and
denatured for 5 min at 75uC followed by 15 min preannealing at
37uC. The hybridization was performed under sealed coverslips
for 3 days at 37uC in a moist chamber. After hybridization, the
slides were washed three times for 5 min in a washing solution
(50% formamide in 26SSC pH 7.0) at 45uC, twice in 26SSC
(pH 7.0) at 45uC, and once in 0.16SSC (pH 7.0) at 45uC.
Biotinylated probe DNA was detected with FITC labeled
streptavidin (Vector Laboratories, Burlingame, CA, USA). The
digoxigenized control DNA was detected with rhodamine labeled
anti-digoxigenin antibodies (Roche Diagnostics, Mannheim,
Germany). Finally the slides were counterstained, and an antifade
solution applied in the same step (Vectashield with DAPI, Vector
Laboratories).
Slides were analyzed using a digital image analysis system
(MetaSystems, Altlussheim, Germany), based on an Olympus AX
70 microscope equipped with a cooled CCD camera (Photo-
metrics, Tuscon, AZ, USA). For analyzing differential fluorescence
data we used the MetaSystems ISIS 3 software. The three-color
images with red, green, and blue were acquired from 15–20
metaphases. Chromosome imbalances were detected on the basis
of the fluorescence ratio profile, deviating from the balanced value
(FITC:rhodamine=1). For each chromosome the final ratio
values were prepared from mean values of at least ten
chromosome homologues from separate metaphase spreads.
CGH results were plotted as a series of green to red ratio profiles,
and the interpretation of results followed previously described
protocols [3].
Fluorescence in situ hybridization
FISH was performed on nuclei and metaphase spreads of the cell
lines CWR22 and CWR22-Rv1. Metaphase spreads of lympho-
cytes from a healthy donor were used as a control. The BAC clone
RP11-165H19 (9p13.3, GenBank accession number AQ382511)
was obtained from BACPAC Resource Center Children’s Hospital
(Oakland Research Institute, Oakland, CA, USA) and cohybridized
with a probe specific for the centromere of chromosome 9 (D9Z1;
Oncor, Gaithersburg, MD, USA). Bacterial cultures and DNA
isolation were done according to the BACPAC Miniprep protocol
(http://www.biologia.uniba.it/rmc). Alu-PCR products of the BAC
were used as probes and were biotinylated using nick translation.
Dual color fluorescence in situ hybridization and detection of
fluorescence signals were done as described previously [6].
Quantitative real time PCR
Quantitative real time PCR for gene copy number measurement
was based on a recently described approach [27]. In the present
study, we used predesigned and validated SNP assays (Applied
Biosystems, CA, USA) with the AB 7900 system (Applied
Biosystems). For the validation of the 9p13.3 amplicon two genes
within the amplicon (IL-11RA, AssayID: C__11340987_10 and
DCTN3, AssayID: C__25472566_10) and a gene at at 3p24.2
located in a not altered region in prostate cancer (TOP2B,
AssayID: C__8063527_10) were analyzed.
In a first step, all SNP assays used in this study were run on
a dilution series of normal blood DNA to determine PCR
efficiency (E) of each primer set by the formula E=10
21/s, where s
represents the absolute value of the slope in a plot of the threshold
cycle (CT) against log of input amount. All primers were shown to
have an equal efficiency of approximately E=2 and in relative
efficiency plots comparing the different primers (log of input
amount vs. DCT) the absolute value of the slope was less than 0.1.
Relative gene copy number was then calculated following the
equitation: 2
2DDCT (User bulletin#2, Applied Biosystems). For
calibration normal blood DNA was added in each PCR run. For
genes having both alleles detected by the assay the CT value was
subtracted by 1 based on the shown efficiency of 2. To determine
whether results obtained by real time PCR analysis of the
prostate cancer samples were significantly different from those
obtained for samples from healthy individuals, we determined
a tolerance interval (TI) for the relative gene copy numbers, using
the standard deviation (SD) of CT values for target and reference
genes in 8 healthy individuals according to the equation:
TI=26(SDDCT62). The TI ranged from 1.62 to 3.17 for
DCTN3 and from 1.77 to 2.94 for IL11-RA.
RESULTS
Minimal recurrent regions of alterations
Because of their highly altered genomes and the large volume of
data generated by array analyses, simple visual inspection of
altered loci proved inefficient to identify minimal recurrent regions
of aberration. To analyze the data set, we combined automatic
aberration identification with a modified frequency plot pro-
cedure. Application of weighted frequency analysis to the
autosomes of prostate cancer cell lines revealed multiple regions
of highly recurrent changes. In comparison to our cCGH analyses
several small amplifications and deletion units were only detected
by aCGH, especially in pericentromeric regions and regions near
the telomeres (Fig. 1). The size of the smallest regions of aberration
could be determined to 110 kb for losses at 19q13.41 in cell lines
DU145NIH, DU145-MN1, PC3 125-1L and CWR22-Rv1, and
760 kb for gains at 14q32.11-q32.12 in PC3HOM, PC3-N and PC3-
125-1L. Most chromosomal aberrations as detected by cCGH
were also seen in aCGH. However, more losses were detected with
microarrays and more large regions of gains with metaphase
technique. For the commonly detected regions of aberrations, no
discrepancy between the two methods in assigning gains or losses
to the individual region was observed (table 1).
ArrayCGH of Prostate Cancer
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prostate cancer cell lines and parental cell line vs.
subline comparison
The aCGH results of the parental cell lines PC3HOM, DU145HOM,
LNCaP and CWR22 and their sublines are summarized in
figure 2. For PC3 and DU145, two different branches could be
compared (HOM vs. NIH). Most amazingly, the cytogenetic
constitution of PC3HOM differed markedly from PC3NIH. From
a total of 54 aberrations in both cell lines, only six strong
aberrations could be found in common: losses at 1q, 8p, 10p and
13 and gains at 10q and 17q. The gain of 8q11.2-8q24.3 in
PC3HOM was also observed in PC3NIH showing a minimal size
variation of 100 kb. For DU145HOM and DU145NIH, a good
overall concordance of the genetic composition was found.
Comparing cell lines PC3HOM, DU145HOM, LNCaP and
CWR22 with their derived sublines PC3-N, PC3-125-1L,
DU145-N, LNCaP-CN4-2 and CWR22-Rv1, respectively, a high
congruency of the cytogenetic aberrations between the corre-
sponding cell lines was yielded by aCGH. It is worth mentioning
that besides minor variations of the number of extra regions with
gains or losses of genetic material differences between parental cell
lines and sublines predominantly concerned the extent of
corresponding regions with copy number alterations, as for
Figure 1. Comparison of cCGH (A, C) and arrayCGH (B, D) results from chromosome 9 of CWR22 and chromosome 14 of DU145-MN1. A small
region of gain on 9p close to the centromer (B, arrowhead) and a small deletion on 14q (D, arrowhead) are only detected by arrayCGH.
doi:10.1371/journal.pone.0000769.g001
Table 1. Overview of detected chromosomal aberrations by cCGH and aCGH
..................................................................................................................................................
Chromosomal aberrations
Cell line
no. found with both
techniques found only in arrayCGH found only in cCGH
PC3HOM 26 -1q24.3, -1q32.2, -3q25.1, -3q27.1-q28, +5q11-5q12.2,
+12p12.1-p13, -12p11.2, -12q24.33,
+2p23-p25, +7, +5p14-p15, +11q14-q25
PC3NIH 16 -1q21-q24.3, +1q25.1-q31.3, +1q41, +5q11-q13.1,
-5q32-q33, -17q21.3-q25, +17q21.1
+2p23-p25, +3p, +7
PC3-N 28 -1q21q24.3, +1q25.1-q32.1, +1q43, +17q11, -17q21.31-q25, +2q21-q24, +7p11-p22, +9q22-q34
PC3-125-1L 17 -1q24.3, +1q21.1-q31.3, +1q43, +Xp21.3-p22 +5q11-q13.1, +7, +11q14-q25, 12q21-q24, +17q22-q25
Du145Hom 12 +9p13.2-p13.3, +9p21-q34, +12p11.1-p13 +2p14-p25, +7p11.2-p22, +10q22-q26, +11q11-q25,
+12q11.2-p24.3, +15, +16q21-q24
DU145NIH 16 +9p13.2-p13.3, -11p11p15, -17p13.2 +2p14-p25, +10q22-q26, +11q11-q25, +12q11.2-p24.3, +15,
+16q21-q24
Du145-MN1 15 +1p12, +11p15.4, 12p12.1, -14q21.3, -17q12, -19q13.4 +2p14-p25, +10q22-q26, +11q13-q14, +15, +16q21-q24
LNCaP 8 -1p33, -11q21.1-q34, -13, -19q13.2-q13.43 -19p13.3
LNCaP-CN4-2 13 -11q12.1, -19q13.2-q13.33 +1q21-q25, +3q24-q26, +5, +9p
CWR22 14 +9p13.3 +8p21-p23, +10q25-q26
CWR22-RV1 20 -2p, -9p21-p24
doi:10.1371/journal.pone.0000769.t001
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PLoS ONE | www.plosone.org 4 August 2007 | Issue 8 | e769example was observed for the regions with gains at 12q and 15q in
PC3HOM vs. PC3-N and for the regions with losses at 2q, 4q, 6q
and 13q21.33 in LNCaP vs. LNCaP-CN4-2.
Validation of the amplified pericentromeric region
9p13.3 using FISH analysis and quantitative real
time PCR
A novel 1.7 Mb region with copy number gains was consistently
recognized in the cell lines CWR22 and CWR22-Rv1 and was
mapped to the pericentromeric 9p13.3 subband. The presence of
this amplicon in the cell lines CWR22 and CWR22-Rv1 was
confirmed by metaphase FISH using a BAC clone (RP11-165H19)
from the amplified region and a probe specific for the centromere
of chromosome 9 (Fig. 3A and B). Optimal signal and lack of cross
hybridization was verified using normal metaphase spreads
(Fig. 3C). This BAC clone contained two genes, IL-11RA and
DCTN3, which were already thought to play a role in prostate
cancer growth [13].
Based on gene localization and annotated gene function, we
selected these two candidate genes for gene copy number
measurements in the prostate cancer cell lines and 20 primary
prostate carcinoma samples using quantitative real time PCR. IL-
11RA showed a significant increase in gene copy number above
normal in CWR22 and CWR22-Rv1 and in 15 out of 20 (75%)
primary prostate cancer tumor samples (Fig. 4). For DCTN3,n o
copy number gain was detected in any cell line and in only 2 out of
the 20 (10%) prostate cancer tumor samples. The control gene
TOP2B at 3p24.2 was proved unchanged compared to normal
blood (data not shown).
DISCUSSION
Although prostate cancer cell lines have been previously analyzed
by aCGH utilizing cDNA microarray platforms [12,13,15–20], we
demonstrate in this study the feasibility of a longmer oligonucle-
otide set, originally designed for expression analysis, for a high-
resolution genomic profiling of nine prostate cancer cell lines. The
microarray data for this study have been submitted to NCBI GEO
with accession GSE7376. Compared to cCGH, we detected more
deletions and small regions of gains with aCGH, especially in
pericentromeric regions and regions near the telomeres, where
cCGH is known not to deliver reliable informations on DNA
imbalances. On the other hand, large regions of gains as revealed
by cCGH encompassing almost the whole arm of chromosomes
were overlooked by aCGH. Similar observations were also
reported by Saramaki et al. (2006) [13] using cDNA-based
aCGH. Besides normalization artifacts one might argue that these
differences could result from the DNA amplification step for
aCGH in our study, whereas non-amplified DNA was used for
cCGH. Although whole-genome amplification by phi29 poly-
merase may add some bias and increase background noise, it is
regarded the most unbiased approach compared to PCR-based
DNA amplification procedures [28]. As any DNA amplification
step seems inevitable in the study of primary prostate cancer
samples, we used an amplification step in our study even though
DNA quantity was not a limiting factor when working with cell
lines.
Our aCGH findings are in good agreement with the data
reported in the literature for PC3, DU145, LNCaP, and CWR22
[12,13,15–20]. However, an interesting side aspect of our study is
Figure 2. Whole genome plot of gained (A) and lost (B) chromosomal regions of 11 prostate cancer cell lines, as detected with aCGH. Numbers
above the plot indicate chromosome numbers and vertical lines boundaries between chromosomes.
doi:10.1371/journal.pone.0000769.g002
Figure 3. Validation of amplicons by FISH analysis on cell lines.
Identification of increased copies of signals of the BAC clone RP11-
165H19 mapped to 9p13.3 amplicon in cell line CWR22 and CWR22-Rv1
(A and B). C Optimal signal and lack of cross hybridization was verified
using normal metaphase spreads showing two signals for each probe.
BAC clone RP11-165H19 signals are green; red signals indicate
chromosome 9 centromere (D9Z1).
doi:10.1371/journal.pone.0000769.g003
ArrayCGH of Prostate Cancer
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PC3 branches, which were held in two different labs (PC3HOM vs.
PC3NIH). The presumed genomic instability of cell lines may lead to
genetic divergency, what has to be considered when comparing
findings from different labs on seemingly the same cell lines. A
quality management system, which includes details of the genetic
composition of the individually used cell lines, seems prudent.
Concerning the comparison of parental cell lines and sublines, no
gross differences in the cytogenetic composition were found by
aCGH. Differences predominantly concerned the boundaries of
corresponding regions with copy number alterations. These findings
are in contrast to our previous cCGH studies demonstrating several
extra regions of DNA copy number alterations in the sublines
compared to the parental cell lines [4]. An explanation might be
technical, as the previously reported differences mainly involved
large chromosome regions, which are detected with a lower
sensitivity by aCGH compared to cCGH, as was discussed above.
As a validation of the high resolution of aCGH, we further
analyzed a small amplification unit of 1.7 MB in the pericen-
tromeric region of chromosome 9 at 9p13.3, which was found in
the xenograft-derived cell lines CWR22 and CWR22-Rv1 by
aCGH but not by cCGH. Interestingly, Saramaki et al. (2006) [13]
also found this region by aCGH to be amplified in the prostate
cancer xenograft LuCaP35. They confirmed their results by BAC-
FISH and demonstrated amplification and overexpression of the
ubiquitin-conjugating enzyme gene E2R2 (UBE2R2), the dynactin
3 gene (DCTN3) and the WD repeat domain 40A gene (WDR40A)
at 9p13.3. Using a real time PCR technique, we further quantified
the copy number of the interleukin 11 receptor alpha gene (IL-
11RA) and the dynactin 3 gene (DCTN3) both revealing the highest
log2 ratio in aCGH within 9p13.3. IL-11RA was found with the
highest copy number gain in CWR22, CWR22-Rv1, DU145HOM
and DU145MN1 suggesting IL-11RA as the putative target gene of
this amplicon. We, therefore, screened 20 primary prostate cancer
samples and found 75% of the tumors harboring an IL-11RA copy
number gain alone, none of DCTN3 alone, and 10% of both genes.
Mean copy number gain for IL-11RA was approximately 4-fold.
These data emphasize our initial assumption that IL-11RA
represents the amplification target rather than DCTN3. This
hypothesis is further strengthened by immunohistochemical
studies [29,30] and the cancer profiling database Oncomine
TM
(www.oncomine.org) which both reveal high overexpression of IL-
11RA in prostate cancer compared to normal prostate tissue. IL-
11RA encodes a specific receptor for IL-11 and belongs to the
family of gp130-dependent cytokine receptors, which include
receptors for IL-6, leukemia inhibitory factor, ciliary neurotrophic
factor, oncostatin M, and cardiotrophin [31]. An important
signaling system activated by IL-11RA and other members of this
receptor family is the Janus kinase-signal transducer and activator
of transcription (Jak-STAT) pathway with STAT3 having a well
studied importance in prostate carcinogenesis [32]. Moreover,
activated STAT3 is believed to play a key role in androgen
receptor activation in the absence of androgens, one explanation
of hormone refractory growth of prostate cancer [33]. Whether IL-
11RA is causative in prostate cancer growth needs to be
investigated in further studies.
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Figure 4. DNA copy number quantification of DCTN3 and IL11-RA genes in prostate cancer cell lines and 20 primary prostate carcinoma samples
using quantitative real time PCR. IL-11RA showed a significant increase in gene copy number above normal in CWR22, CWR22-Rv1, DU145HOM and
DU145-MN1 and in 15 out of the 20 (75%) prostate cancer samples. For DCTN3, no copy number gain was detected in any cell line and in only 2 out of
the 20 (10%) prostate cancer samples. Values above cut off line being assigned as increased gene copy number compared to normal.
doi:10.1371/journal.pone.0000769.g004
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